Sakar Healthcare

** Shares of India's Sakar Healthcare SAKA.NS jump 5% to 345 rupees

** Drugmaker gets approval to market its injection used to treat colorectal cancer in the European Union

** Adds, expects other products, including oral solids and injections, to also receive EU approvals within the next few months

** Trading vols ~115k shares vs 30-day avg of ~25k shares

** YTD stock had risen ~16%

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

April 16 (Reuters) - Sakar Healthcare Ltd SAKA.NS:

• SAKAR HEALTHCARE LTD - ENTERS 9 AGREEMENTS TO BOOST ONCOLOGY PRODUCT EXPORTS

• SAKAR HEALTHCARE LTD - 7 AGREEMENTS UNDER FINAL NEGOTIATIONS FOR ED BIG-4 AND LATIN AMERICA

Source text: ID:nNSE6LKY6N

Further company coverage: SAKA.NS

(([email protected];))

July 22 (Reuters) - Sakar Healthcare Ltd SAKA.NS:

• SAKAR HEALTHCARE - RE-APPOINTS SANJAY S. SHAH AS MD

• SAKAR HEALTHCARE - RE-APPOINTS AARSH S. SHAH AS JOINT MD

Further company coverage: SAKA.NS

(([email protected];))

July 8 (Reuters) - Sakar Healthcare Ltd SAKA.NS:

• SAKAR HEALTHCARE - STARTED PRODUCT DOSSIER SUBMISSION IN ANTI-CANCER SEGMENT TO OVERSEAS COUNTRIES

Source text for Eikon: ID:nNSE5Z7w0z

Further company coverage: SAKA.NS

(([email protected];))

** Shares of Sakar Healthcare SAKA.NS rise as much as 9.8% before trimming some gains, last up 1.4% at 341.75 rupees

** Pharma products maker said its oncology unit has entered into deal with seven overseas partners for supply of its oncology products

** Stock eyes busiest trading day since early March, volumes at 8.7x the 30-day avg

** Including session's gains, stock down ~15% so far this year

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

March 6 (Reuters) - Sakar Healthcare Ltd SAKA.NS:

• SAKAR'S ONCOLOGY (ANTI-CANCER) UNIT RECEIVES EU GMP APPROVAL

Source text for Eikon: [ID:]

Further company coverage: SAKA.NS

(([email protected];))

Nov 21 (Reuters) - Sakar Healthcare Ltd SAKA.NS:

• TO ISSUE SHARES AND WARRANTS BY WAY OF PREFERENTIAL ISSUE

• TO ISSUE UP TO 400,000 SHARES AT ISSUE PRICE OF 384 RUPEES PER SHARE

• TO ISSUE UP TO 500,000 WARRANTS AT ISSUE PRICE OF 384 RUPEES PER WARRANT

Source text for Eikon: ID:nNSE4nQLGH

Further company coverage: SAKA.NS

(([email protected];;))

Aug 3 (Reuters) - Sakar Healthcare Ltd SAKA.NS:

• APPROVED ISSUANCE OF SHARES BY WAY OF PREFERENTIAL ISSUE ON PRIVATE PLACEMENT BASIS

• APPROVED TO CREATE, OFFER, ISSUE AND ALLOT UP TO 2.3 MILLION SHARES AT ISSUE PRICE OF 259.75 RUPEES PER SHARE

Source text for Eikon: ID:nNSE4fXKw9

Further company coverage: SAKA.NS

(([email protected];;))

July 5 (Reuters) - Sakar Healthcare Ltd SAKA.NS:

• SAKAR HEALTHCARE LTD - WHO GMP APPROVAL RECEIVED FOR ONCOLOGY INJECTION UNIT AT VERTICALLY INTEGRATED ONCOLOGY PRODUCT MANUFACTURING SITE

Source text for Eikon: ID:nNSE1YyZ5y

Further company coverage: SAKA.NS

(([email protected];;))

** Shares of Sakar Healthcare Ltd SAKA.NS rise as much as 9.56% to 259.50 rupees, highest in nearly four months since Jan. 23

** Uptick after the pharmaceutical products maker enters into an agreement with Swiss firms Ferring Pharmaceuticals and Bazell Pharma LLP

** Agreement to develop novel drug delivery system for two oncology products, SAKA says in an exchange filing

** SAKA scaling up batches at its oncology formulation-manufacturing unit in Gujarat, says initial outcomes are encouraging

** Once the two products get regulatory approvals, Ferring Pharma and Bazell Pharma intend to use them in oncology facilities across the world

** Trading volume is 82,926 shares as of 12:31 p.m. IST, 5.4 times the 30-day avg

** The relative strength index of the stock is 70, suggesting it may be overbought - Refinitiv data

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

May 11 (Reuters) - Sakar Healthcare Ltd SAKA.NS:

• ENTERED INTO AGREEMENT WITH PHARMACEUTICAL ORIENTED SERVICES

• AGREEMENT FOR PROCESS OF DEVELOPMENT OF PATENT NON-INFRINGING FILM COATED TABLETS IN FOUR STRENGTHS

Source text for Eikon: ID:nNSE2NNHC9

Further company coverage: SAKA.NS

(([email protected];;))